Best Neuroendocrine Tumor Podcasts (2024)

1
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations 28:28

2h ago28:28

28:28

In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including: The diagnosis and typical presenting symptoms of GEP-NETs Findings from recent key phase III studies including NETTER-2 and CABINET Recommendations for treatment sequencing No…

1
Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors 59:19

20d ago59:19

59:19

Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.By Neil Love, MD

1
Neuroendocrine Tumors | Pamela Kunz, MD 26:44

27d ago26:44

26:44

Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors | Faculty Presentation 2: Later-Line Treatment for Advanced NETs — Pamela Kunz, MD CME information and select publicationsBy Dr. Neil Love

1
Episode 37: Supportive Oncology for Neuroendocrine Cancer 42:58

24d ago42:58

42:58

What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fe…

1
Metastatic Non-Small Cell Lung Cancer | The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer 1:00:08

1h ago1:00:08

1:00:08

Featuring perspectives from Dr Edward B Garon and Dr Luis Paz-Ares, including the following topics: Introduction: Ivonescimab (0:00) First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Tumor Mutation — Dr Garon (11:47) Promising Therapeutic Strategies for Patients with Progressive Metastatic NSCLC — Dr Paz-Ares…

1
The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer 1:00:07

32m ago1:00:07

1:00:07

Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.…

1
NEJM Interview: Jose Figueroa on the potential effects of the results of the 2024 elections on health care access, affordability, and equity. 21:26

7h ago21:26

21:26

Jose Figueroa is an associate professor of health policy and management at the Harvard T.H. Chan School of Public Health and an assistant professor of medicine at Harvard Medical School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.M. McWilliams and S.B. Dusetzina. Affordability of Health Care in the United…

1
The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer 1:00:07

9h ago1:00:07

1:00:07

Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations, moderated by Dr Neil …

1
Chronic Lymphocytic Leukemia | Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series 58:59

6d ago58:59

58:59

Featuring perspectives from Dr Matthew S Davids, including the following topics: Introduction: Is Chronic Lymphocytic Leukemia (CLL) the New Chronic Myeloid Leukemia? Cases We Didn’t Hear About Last Week (0:00) Case: A man in his early 70s with IGHV-unmutated CLL (trisomy 12, del[17p]) receives ibrutinib for several years and is switched to acalabr…

1
Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series 58:58

6d ago58:58

58:58

Dr Matthew S Davids from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews current available data and ongoing investigational treatment approaches for chronic lymphocytic leukemia, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here.By Research To Practice

1
Diffuse Large B-Cell Lymphoma | Data + Perspectives: Clinical Investigators Discuss the Current and Future Management of Diffuse Large B-Cell Lymphoma 1:00:32

7h ago1:00:32

1:00:32

Featuring perspectives from Dr Christopher Flowers, Prof Grzegorz S Nowakowski and Dr Laurie H Sehn, moderated by Dr Flowers, including the following topics: Introduction (0:00) Front-Line Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn (1:56) Case: A woman in her late 40s with epidural DLBCL and a compression fracture (Dr Flowers) (1…

1
NEJM Interview: Jean Nachega on the mpox Public Health Emergency of International Concern. 9:20

12h ago9:20

9:20

Jean Nachega is an associate professor of infectious diseases and microbiology and of epidemiology at the University of Pittsburgh School of Public Health and a professor of medicine at Stellenbosch University. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.B. Nachega and Others. Mpox in Pregnancy — Risks, Ve…

1
Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR | The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR ... 58:14

16h ago58:14

58:14

Featuring perspectives from Dr Ibiayi Dagogo-Jack and Dr Corey J Langer, including the following topics: Introduction: A Model for Targeted Treatment in Non-Small Cell Lung Cancer (NSCLC) (0:00) NSCLC with ALK, ROS1 and NTRK Rearrangements — Dr Langer (9:10) Current and Future Treatment of Metastatic NSCLC with RET, MET, HER2 and KRAS Alterations —…

1
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR 58:13

14h ago58:13

58:13

Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.…

1
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR 58:13

23h ago58:13

58:13

Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR, moderated by Dr Neil Love. Produced by Research …

1
Health Equity and Cancer Prevention 29:02

3d ago29:02

29:02

The Era of Precision Medicine with guest Dr. Cary Gross, Sunday, October 6, 2024 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095By Hosted by Eric Winer

1
Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic ... 59:33

5d ago59:33

59:33

Featuring perspectives from Dr Joshua Brody, Dr Matthew Lunning and Dr Jason Westin, moderated by Dr Lunning, including the following topics: Introduction (0:00) Integration of Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Westin (1:34) Current Role of CAR T-Cell Therapy for Other B-Cell Ly…

1
Non-Small Cell Lung Cancer with EGFR Mutations | The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations 58:19

7d ago58:19

58:19

Featuring perspectives from Dr Joshua K Sabari and Dr Helena Yu, including the following topics: Introduction: Checkpoint Inhibitors and Lung Cancer with an EGFR Mutation (0:00) Current Management of Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutations — Dr Sabari (5:39) Novel Therapeutic Approaches for NSCLC Harboring EGFR Mutations —…

1
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations 58:19

12d ago58:19

58:19

Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.By Neil Love, MD

1
NEJM Interview: Jonathan Oberlander on the implications of the 2024 U.S. elections for health care reform. 8:47

7d ago8:47

8:47

Jonathan Oberlander is a professor of social medicine and of health policy and management at the University of North Carolina at Chapel Hill. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J. Oberlander. Health Care Reform and the 2024 U.S. Elections — Low Visibility, High Stakes. N Engl J Med 2024;391:1169-117…

1
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations 58:19

12d ago58:19

58:19

Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here.…

1
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers 30:45

8d ago30:45

30:45

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical cancer at the ESMO 2024 annual congress including: Phase III PRIMA/ENGOT-OV26/GOG-3012 Final OS Results: Niraparib as First-Line Maintenance in Advanced…

1
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance 32:48

9d ago32:48

32:48

In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including: Contemporary treatment paradigms for patients with CLL Safety and efficacy of current regimens Molecular testing, including when and how to test for BTK inhibitor res…

1
The Era of Precision Medicine 29:02

11d ago29:02

29:02

The Era of Precision Medicine with guest Dr. Katerina Politi, September 29, 2024 Sunday, September 29 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095By Hosted by Eric Winer

1
Breast Cancer | Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer (Companion Faculty Lecture) 27:22

14d ago27:22

27:22

Featuring a slide presentation and related discussion from Dr Tiffany A Traina, including the following topics: Extended follow-up with pembrolizumab/chemotherapy for patients with previously untreated PD-L1-positive metastatic triple-negative breast cancer (mTNBC) (0:00) ASCENT trial: Survival advantage with sacituzumab govitecan versus physician’…

1
Breast Cancer | Oncology Today with Dr Neil Love: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast Cancer 49:41

21d ago49:41

49:41

Featuring an interview with Dr Tiffany A Traina, including the following topics: Choice of chemotherapy to combine with first-line pembrolizumab for metastatic triple-negative breast cancer (mTNBC) (0:00) Ongoing investigations of androgen receptor-targeting agents for metastatic breast cancer (mBC) (8:37) Efficacy and CNS activity of sacituzumab g…

Podcasts Worth a Listen

Neuroendocrine Tumor Podcasts

Podcasts Worth a Listen

Quick Reference Guide